

The pharmaceutical industry in the EU

2.6 MILLION EU JOBS



EVERY JOB IN THE PHARMACEUTICAL INDUSTRY SUPPORTS 3 OTHER JOBS




HIGHLY PRODUCTIVE



HIGHLY QUALIFIED

PRODUCTIVITY IS 2.5 TIMES HIGHER THAN THE MANUFACTURING AVERAGE

PHARMA CONTRIBUTES SIGNIFICANTLY TO THE EU ECONOMY



STRONG ECONOMIC FOOTPRINT
+26,000 INCREASE IN JOBS IN THE EU PHARMA INDUSTRY IN 2000 → 2013



+5% INCREASE



EFPIA Brussels Office
Leopold Plaza Building • Rue du Trône 108
B-1050 Brussels • Belgium
Tel: + 32 (0)2 626 25 55 • Fax: + 32 (0)2 626 25 66
www.efpia.eu • info@efpia.eu

efpia

European Federation of Pharmaceutical Industries and Associations


The EU – US Transatlantic Trade and Investment Partnership (TTIP):

Impact on EU economy, society and patients



www.efpia.eu


The transatlantic industry today



The US is the biggest individual market for the European pharmaceutical industry

EU EXPORTS TO MARKETS OUTSIDE THE EU, 2014

TOTAL €118 BILLION



Key findings*



+€9 BILLION
IN EU PHARMA EXPORTS

+79,000 JOBS



+19,000
NEW HIGH VALUE JOBS
IN THE EU PHARMA INDUSTRY



SUPPORTS AROUND
+60,000
ADDITIONAL JOBS
IN RELATED INDUSTRIES

+8,000 JOBS
IN US PHARMA AFFILIATES IN THE EU
IF TTIP LOWERS FDI BARRIERS
BY 25 PER CENT



Opportunities in TTIP for the Pharmaceutical Industry

Regulatory cooperation:

- * Mutual recognition of Good Manufacturing Practices (GMP) inspections can reduce duplicative inspections of manufacturing sites on both sides of the Atlantic by up to 40%



- * Common procedures for submitting paediatric plans can reduce duplicative and unnecessary testing on children and accelerate delivery of new paediatric medicines

- * Harmonisation of clinical trial results data fields can reduce duplicative submissions of the same data, which creates efficiencies and facilitates information sharing



- * A harmonised approach to the submission of CMC changes would reduce the administrative burdens for both companies and regulatory agencies



+ HORIZONTAL REGULATORY MEASURES AND COOPERATION

Intellectual Property:



- * TTIP can reinforce commitment to shared high level Intellectual Property (IP) principles already in place in both the EU and the US and promote these standards in their respective trade agendas

Market access:

- * TTIP can help promote predictable and transparent pricing and reimbursement processes, supporting access to medicines for patients in Europe



BENEFITS FOR EU PATIENTS

FASTER ACCESS
TO INNOVATIVE
MEDICINES



INCREASED CHOICE
FOR EU PATIENTS
& HEALTH CARE SYSTEMS



FREE UP RESOURCES
FOR COMPANIES
AND REGULATORS

Key findings*



**REDUCING FDI
BARRIERS BY
25 PER CENT**



**INCREASES
EMPLOYMENT IN
TRANSATLANTIC
AFFILIATES BY
10 PER CENT**



+€146 BILLION
VALUE OF EXPORTS
OVERALL



+€9 BILLION
PHARMACEUTICAL



+€117 BILLION
VALUE OF IMPORTS
OVERALL



+€4 BILLION
PHARMACEUTICAL

* Findings are drawn from a study carried out by Copenhagen Economics for EFPIA. The study assesses the economic impacts for the EU from an ambitious pharmaceutical chapter in TTIP

** The study, carried out by Copenhagen Economics and commissioned by EFPIA, relies on key estimates of the impact and reduction potential of non-tariff barriers on transatlantic trade in pharmaceuticals as estimated by the European Commission and CEPR.